Collectively, these results implied that ICB, neoadjuvant or adjuvant chemotherapy, and ERBB therapy can be considered, either alone or in combination, for the treatment of BLCA with the MRS1 phenotype. Here, EGFR is linked to bladder transitional cell carcinoma.